ArticlePloS one2026
A monoclonal antibody raised against Acinetobacter baumannii capsular carbohydrate exhibits cross-species in vitro binding against Pseudomonas aeruginosa.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The emergence of extensively drug-resistant bacterial pathogens such as Acinetobacter baumannii and Pseudomonas aeruginosa necessitates the innovation of non-small molecule therapies. Monoclonal antibodies represent a promising non-small molecule option. By exploiting shared or similar antigenic structures on these pathogens, it may be possible to develop therapeutic antibodies that target both bacterial species. Here we demonstrate that a previously developed monoclonal antibody targeting A. baumannii (MAb10) has cross-species reactivity to P. aeruginosa in in vitro assays. Despite MAb10's distinct efficacy against A. baumannii, no efficacy was detected against P. aeruginosa in our mouse models of infection. Nevertheless, the unique carbohydrate structures targeted by MAb10 and shared by numerous bacterial species may underscore a possible strategy for developing therapeutic antibodies that can treat infections caused by multiple pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.